OncoSec and Merck to begin Phase II combination trial to treat metastatic melanoma

US-based biotechnology company OncoSec has entered a clinical trial collaboration and supply agreement with Merck to begin the Phase II PISCES clinical trial of ImmunoPulse IL-12 and keytruda combination for the treatment of patients with metastatic …
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news